Moderna shares sink after leaked cancer data missed expectations

What happened: Moderna shares fell after leaked data on its melanoma vaccine treatment missed expectations. The treatment cut the risk of recurrence or death by 58%. Key numbers: 58% reduction in risk of recurrence or death; Moderna shares sank. Why it matters: The result failed to exceed Wall Street's lofty expectations, and the leak preceded the share decline. Coverage: 4 outlets in 24h

Moderna shares fell after leaked data on its melanoma vaccine treatment missed expectations. The treatment cut the risk of recurrence or death by 58%.

The result failed to exceed Wall Street's lofty expectations, and the leak preceded the share decline.